Natural History Study of Children With Metachromatic Leukodystrophy
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- Shire
- 入组人数
- 1
- 试验地点
- 14
- 主要终点
- The primary endpoint of this study is the change from baseline in motor function using the GMFM-88 total (percent) score.
研究概览
简要总结
The purpose of this study is evaluate the natural course of disease progression related to gross motor function in children with metachromatic leukodystrophy (MLD).
详细描述
Metachromatic leukodystrophy (MLD) is an inherited, autosomal recessive disorder of lipid metabolism characterized by deficient activity of the lysosomal enzyme, arylsulfatase A (ASA). MLD is a rare genetic disease that occurs in most parts of the world. The estimated overall incidence of the disease in the western world is approximately 1 in 100,000 live births.
This study is a multicenter, observational, longitudinal study that plans to enroll up to 30 patients with onset of MLD-related signs and symptoms prior to 30 months of age and who are less than 12 years of age. Patients will participate in this study for approximately 114 weeks (Screening through Follow-up) and will be assessed at defined intervals for disease status.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of MLD by both:
- •arylsulfatase A (ASA) deficiency by assay in leukocytes AND
- •elevated sulfatide in urine
- •Appearance of the first symptoms of disease at or before 30 months of age.
- •A GMFM-88 total (percent) score greater than or equal to 40 at the screening examination.
- •The patient is less than 12 years of age at the time of enrollment.
- •The patient and his/her parent or legally authorized representative(s) must have the ability to comply with the clinical protocol.
- •Patient's parent or legally authorized representative(s) must provide written informed consent prior to performing any study-related activities. Study-related activities are any procedures that would not have been performed during normal management of the patient.
排除标准
- •History of hematopoietic stem cell transplantation.
- •The patient has any known or suspected hypersensitivity to agents used for anesthesia or is thought to be at an unacceptably high risk for associated potential complications of airway compromise or other conditions.
- •Any other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study.
- •The patient is enrolled in another clinical study that involves the use of any investigational product (drug or device) within 30 days prior to study enrollment or at any time during the study.
结局指标
主要结局
The primary endpoint of this study is the change from baseline in motor function using the GMFM-88 total (percent) score.
时间窗: Week 0 to Week 104
次要结局
- The change from baseline in cognitive function using the Mullen Scales of Early Learning.(Week 0 to Week 104)
- Reporting of any study procedure-related nonserious AEs and/or any SAEs(Week 0 to Week 114)
- The change from baseline in domain-specific Caregiver Observed MLD Functioning and Outcomes Reporting Tool.(Week 0 to Week 104)
- The change from baseline in ability to swallow as assessed by the Functional Endoscopic Evaluation of Swallowing.(Week 0 to Week 104)
- The change from baseline in nerve conduction as measured by the electroneurography.(Week 0 to Week 104)
- The change from baseline in the adaptive behavior composite standard score as measured by the Vineland Adaptive Behavior Scales.(Week 0 to Week 104)